Contineum Therapeutics, Inc.
CTNM Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$8.31
KIRA · Stoqly’s AI analyst, in plain words
- Contineum Therapeutics, Inc. lost $60.0M in fiscal 2025.
- Free cash flow was −$55.5M in fiscal 2025, — of revenue.
Market cap
$311M
P/E
—
Revenue
—
Net income
−$60.0M
Free cash flow
−$55.5M
Operating margin
—
Contineum Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$60.0M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Contineum Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Contineum Therapeutics, Inc.
- CIK
- 0001855175
Contineum Therapeutics, Inc. · CTNM
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $50.0M | $0.0M | — |
| Revenue growth | — | −100.0% | — |
| Operating margin | 32.2% | — | — |
| Net income | $22.7M | −$42.3M | −$60.0M |
| Net margin | 45.4% | — | — |
| Diluted EPS | $0.08 | −$2.18 | −$2.17 |
| Cash | |||
| Cash from operations | $19.3M | −$32.8M | −$55.3M |
| Capital expenditure | $0.4M | $0.5M | $0.2M |
| Free cash flow | $18.9M | −$33.4M | −$55.5M |
| FCF margin | 37.9% | — | — |
| Share count change | — | 470.0% | 43.1% |
| Debt and strength | |||
| Cash and short-term investments | $125M | $205M | $263M |
| Shareholders' equity | −$67.9M | $198M | $261M |
| Current ratio | 23.3x | 20.7x | 27.5x |
| Interest coverage | 77.3x | — | — |
| Returns and quality | |||
| Return on equity | — | −64.9% | −26.1% |
| Return on tangible equity | — | −21.3% | −23.0% |
| Piotroski F-score | — | 1 | — |
| Altman Z'' | −7.4 | 16.7 | 19.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.9M
3 insiders
Of sales under plans
100%
$1.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Contineum Therapeutics, Inc. · CTNM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $8.31 a share, the company is worth $311M.
Source: SEC EDGAR XBRL filings (CIK 0001855175). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.